Loading
Dozens of companies sell blood tests for tumour DNA and they report different results on the same sample. Government-issued reference samples with known amounts of tumour DNA would expose the differences.
ctDNA assays differ in limit of detection, variant calling and reporting; head-to-head comparisons on clinical samples show discordance, especially at low variant allele fractions where MRD decisions are made. A national metrology institute issuing certified reference plasma (fragmented DNA with defined variants at defined allele fractions, including sub-0.1% levels) and requiring assays to report performance on them in labelling would make claims comparable and detect drift over time.
Shares Variant allele frequency (VAF), Natera, Guardant Health, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.
Shares Natera, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares Variant allele frequency (VAF), ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), Biomarkers are not validated or standardised, MRD / molecular residual disease testing.
Shares Natera, Guardant Health, Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Natera, Guardant Health, ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment, Minimal / molecular residual disease (MRD).